Mycophenolic acid antagonizes the activation of cultured human mesangial cells

被引:69
作者
Dubus, I
Vendrely, B
Christophe, I
Labouyrie, JP
Delmas, Y
Bonnet, J
Combe, C
机构
[1] INSERM, U441, F-33600 Pessac, France
[2] Univ Bordeaux 2, F-33076 Bordeaux, France
关键词
collagen; fibronectin; smooth muscle alpha-actin; immunosuppression; chronic allograft rejection; progressive glomerulosclerosis; organ transplantation;
D O I
10.1046/j.1523-1755.2002.00514.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Activation of mesangial cells is observed in several forms of chronic renal disease, and in culture conditions upon stimulation by fetal calf serum (FCS), or agonists such as transforming growth factor beta (TGF-beta). Mycophenolate mofetil (MMF), the precursor of mycophenolic acid (MPA), is currently used in organ transplantation and has been shown to be protective in clinical and experimental glomerulonephritis. This study assessed the effects of MPA on markers of human mesangial cells (HMC) activation. Methods. Primary cultures of HMC and of an immortalized HNIC clone (IP15 cells characterized in this report) were stimulated either by FCS or by TGF-beta, and treated by MPA at clinically relevant concentrations (1 to 10 mumol/L) for 24 hours to 14 days. HNIC proliferation, smooth muscle alpha-actin (SMA), collagen type I alpha-1 chain (coll I) and fibronectin synthesis were used as markers of HNIC phenotypic activation. Results. Exposure of HNIC to MPA inhibited proliferation induced by FCS without cytotoxicity. MPA counteracted the stimulatory effects of FCS and TGF-beta on coll I mRNA and protein and fibronectin protein. SMA expression was increased upon exposure to MPA, without cell hypertrophy. Conclusion. Treatment of cultured HNIC with MPA inhibited mesangial cell proliferation and matrix production induced by stimulation with either FCS or TGF-beta. Such mechanisms may contribute to the favorable effects of treatment using mycophenolate mofetil in chronic fibrotic kidney diseases, including chronic allograft rejection.
引用
收藏
页码:857 / 867
页数:11
相关论文
共 43 条
  • [1] Allison AC, 1996, CLIN TRANSPLANT, V10, P77
  • [2] ALLISON AC, 1993, TRANSPLANT P, V25, P67
  • [3] Mycophenolate mofetil and its mechanisms of action
    Allison, AC
    Eugui, EM
    [J]. IMMUNOPHARMACOLOGY, 2000, 47 (2-3): : 85 - 118
  • [4] ARDAILLOU R, 1996, KIDNEY, P99
  • [5] Mycophenolate mofetil: implications for the treatment of glomerular disease
    Badid, C
    Desmouliere, A
    Laville, M
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (09) : 1752 - 1756
  • [6] Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney
    Badid, C
    Vincent, M
    McGregor, B
    Melin, M
    Hadj-Aissa, A
    Veysseyre, C
    Hartmann, DJ
    Desmouliere, A
    Laville, M
    [J]. KIDNEY INTERNATIONAL, 2000, 58 (01) : 51 - 61
  • [7] Alterations of endothelial nucleotide levels by mycophenolic acid result in changes of membrane glycosylation and E-selectin expression
    Bertalanffy, P
    Dubsky, P
    Wolner, E
    Weigel, G
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1999, 37 (03) : 259 - 264
  • [8] TGF-beta in kidney fibrosis: A target for gene therapy
    Border, WA
    Noble, NA
    [J]. KIDNEY INTERNATIONAL, 1997, 51 (05) : 1388 - 1396
  • [9] Successful mycophenolate mofetil treatment of glomerular disease
    Briggs, WA
    Choi, MJ
    Scheel, PJ
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (02) : 213 - 217
  • [10] Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
    Chan, TM
    Li, FK
    Tang, CSO
    Wong, RWS
    Fang, GX
    Ji, YL
    Lau, CS
    Wong, AKM
    Tong, MKL
    Chan, KW
    Lai, KN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) : 1156 - 1162